THE FITC-DEXTRAN (MW 10000) DIARIES

Hepatic impairment No dose adjustment is required in patients with gentle or average (Child-Pugh A or B) hepatic impairment (see segment five.two). Exposure to midostaurin and its Energetic metabolite CGP62221 is significantly decreased in patients with extreme hepatic impairment than that in clients with typical hepatic perform (see segment five.N